ArticleBioactive materials2027
Tissue engineering polymeric formulations enable lymphangiogenesis for myocardial repair.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Emerging evidence emphasizes the pivotal contribution of cardiac lymphatic activation following ischemic heart injury, with induced lymphangiogenesis driving edema resolution and inflammatory cell clearance. The aim of this study was to identify a bioactive small molecule with pro-lymphangiogenic activity and to develop a tissue engineering polymeric formulation for sustained local delivery in myocardial repair. Methods: Through a high-throughput screen, we identified the bioactive molecule β-(3,4-dihydroxyphenyl) lactic acid (3,4-DHPLA) as a potent stimulator of lymphatic endothelial cells (LECs). To leverage this finding, we engineered a tissue engineering polymeric formulation (TEPF) to promote lymphangiogenesis during myocardial repair. The TEPF was fabricated via an integrated strategy combining 3D printing and near-field electrospinning to incorporate 3,4-DHPLA into a biodegradable polyurethane scaffold. The resulting structure mimics the microstructure of the cardiac extracellular matrix while supporting the microenvironment-responsive release of 3,4-DHPLA. Results: We evaluated the therapeutic efficacy of TEPF in rat and porcine ischemia/reperfusion injury models, which markedly improved cardiac function and significantly attenuated adverse ventricular remodeling. Single-cell RNA sequencing and Conclusions: Thus, the tissue engineering polymeric formulations may enable sustained drug release during myocardial tissue repair, thereby alleviating the pain of injection administration for patients with cardiovascular diseases and potentially facilitating patient-friendly use of other functional molecules-based therapeutic tissue engineering formulations through durable delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.